Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and Bioavailability of Tinengotinib (TT-00420) in Healthy Volunteers
NCT04705922Phase 1Completed
- Sponsor
- TransThera Biosciences
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tinengotinib in cholangiocarcinoma (CCA), triple-negative breast cancer (TNBC) and solid tumor (3 arms), sponsored by TransThera Biosciences. Primary endpoints: Area under the curve from time zero to infinity, Area under the curve from time zero to time t and 1 more. Started Dec 2020; status: completed.
02
Drugs
tinengotinib
03
Conditions
cholangiocarcinoma (CCA)triple-negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT04705922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705922.